Press Release

MoFo Advises on $207 Million Financing of CBC Group’s Two Biotechnology Portfolio Companies

05 May 2022

Morrison & Foerster LLP represented two of CBC Group’s biotechnology portfolios companies , RVAC Medicines (“RVAC”), an emerging messenger RNA (mRNA) platform company with R&D centers in Boston and Singapore, and Ensem Therapeutics (“Ensem”), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, in their financing.

MoFo advised RVAC in its series A and series B financing, bringing the company’s total funds raised to $140 million. Proceeds from this financing round will be used for preclinical and clinical development of the company’s vaccine and therapeutics programs and building world-class R&D centers and manufacturing capabilities.

MoFo also advised Ensem in its $67 million Series A financing. The financing is led by GGV Capital, with co-investment by Pavilion Capital, Cenova Capital, and Mitsui & Co. Global Investment, Inc. Proceeds will be used to further advance the company’s Kinetic EnsembleTM platform and to accelerate its R&D pipeline.

The MoFo teams advising on both transactions are led by Shanghai M&A Partner Ruomu Li and Shanghai M&A/TTG Partner Chuan Sun, together with Shanghai Associate Wenlan Geng and Chloe Liu.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.